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Summary We compared para-, meta- and ortho-isomers of meso-tetra(hydroxyphenyl)porphyrin (p-, m- and
o-THPP) and the potassium salt of the para compound (K-p-THPP) with haematoporphyrin derivative
(HpD) and Photofrin II in their ability to sensitise tumours, skin and brain to light. HpD and Photofrin II
induced modest tumour photosensitisation at the cost of substantial skin and brain sensitisation. At doses low
enough to keep sensitisation of these normal tissues within acceptable limits, tumour sensitisation was
sufficient to give necrosis only 2mm deep after exposure to 1OJcm-2 light.
In contrast, doses of p-THPP, K-p-THPP and m-THPP that produced skin and brain sensitivity within
acceptable limits sensitised tumours enough to give 4-9mm necrosis after OJCcm-2 light. m-THPP was, on a
molar basis, about 25-30 times as potent as HpD and Photofrin II in sensitising tumours. o-THPP was also
a potent tumour photosensitiser, but induced a prohibitive degree of skin photosensitivity even at low doses.
It is unlikely that these differences in relative selectivity are due to differences in such photophysical
parameters as optimum activating wavelength (which would affect tissue penetration by light), or light
absorption, and physicochemical factors that determine tissue localisation may be involved.
The high tumour sensitising potency and favourable tissue selectivity of m-THPP, p-THPP and K-p-THPP
make them promising candidates for clinical tumour phototherapy.
'Haematoporphyrin derivative' (HpD) has for more
than a decade been almost the sole agent used in
clinical tumour phototherapy. However, it is well-
known to have a number of drawbacks. First, it is
a complex mixture, consisting in large part of
materials inactive in vivo (Berenbaum et al., 1982)
and its composition varies between batches in a
way that is not entirely controllable. Second, tissue
penetration of light in the range able to aca- ate
photosensitisers increases with wavelength (Eichler
et al., 1977; Wan et al., 1981), and thus, for
effective tumour damage, illumination should be at
the longest wavelength that excites the sensitiser.
For HpD, this is around 620-630nm, but is a
poorly effective excitation band for this sensitiser.
Other disadvantages relate to tissue selectivity of
photosensitisation. HpD sensitises skin, so that
patients must avoid strong light for some weeks
after treatment. HpD also sensitises other normal
tissues, which compromises its use against tumours
of certain sites, especially brain (Rounds et al.,
1982; Bonnett et al., 1984; Berenbaum et al., 1986).
We suggested (Bonnett & Berenbaum, 1983;
Bonnett et al., 1984; Berenbaum et al., 1982) that
the constituent of HpD responsible for tumour
sensitisation was a dimer, possibly di-
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haematoporphyrin ether or ester. This idea has
been endorsed by others (Dougherty, 1984b; Kessel
& Cheng, 1985), but the evidence is incomplete. A
partly purified preparation of HpD, said to be
enriched in di-haematoporphyrin ether, has become
available under the name Photofrin II. It is claimed
that this preparation is a more potent tumour
sensitiser than HpD and, in therapeutically
equivalent dosage, has less skin sensitising activity
(Dougherty, 1984). However, this material shares
the main disadvantages of HpD, i.e., incompletely
defined composition and weak excitation by red
light.
It has long been apparent that it would be
preferable to have photosensitisers that were pure
materials, activated strongly by red light (and
preferably at the more penetrating wavelengths
above 620-630nm). Favoured candidates are
phthalocyanines (Ben-Hur & Rosenthal, 1985;
Chan et al., 1986) and chlorins (Kessel & Dutton,
1984). We have studied a wide range of porphyrins
and related compounds. Included in these were a
series of known meso-tetra(hydroxyphenyl)-
porphyrins (Gottwald & Ullman, 1969; Little
et al., 1975; Semeikin et al., 1983) which were
selected since they, or their anions, were expected
to show enhanced absorption in the red region
(Milgrom, 1983). In the event, these compounds
proved to be highly effective tumour photo-
sensitisers with interesting and possibly useful tissue
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selectivity. We also synthesised a number of
analogues of these substances. Preliminary results
on these compounds were published in the patent
literature (British Patent Application 84/29845,
November 1984) and more extensive work on the
hydroxyphenyl derivatives is now presented.
Materials and methods
Porphyrin photosensitisers
The porphyrins used in the present work are known
compounds which are available by the Rothemund
synthesis (Adler et al., 1967). We have improved
the syntheses and purification procedures in various
ways which will be described elsewhere. The
structures, names and abbreviations are shown in
Figure 1.
5, 10, 15, 20-Tetra(p-hydroxyphenyl)porphyrin (I)
was prepared from p-acetoxy-benzaldehyde and pyr-
role along the general route outlined by Little et al.
(1975) but with considerable improvements. Mass
spectrum (FAB): M+ +H, 679 (C44H30N404 +H
requires 679). The potassium salt (II) was prepared
as follows. The porphyrin (I) (29mg) was dissolved
in the minimum volume oftetrahydrofuran to which
was added dropwise a concentrated solution of
potassium methoxide (freshly prepared by dis-
solving potassium in anhydrous methanol) until the
solution turned green and precipitate was formed.
The precipitate was collected at the centrifuge,
washed with a little tetra-hydrofuran and dried in
vacuo to give the potassium salt of I as a dark
purple solid (24mg). This is regarded as the
tetrapotassium tetraphenoxide (Milgrom, 1983).
Attempts to purify this led to hydrolysis of the salt,
and it was used without further purification.
5, 10, 15, 20-Tetra(m-hydroxyphenyl)porphyrin
(III) was prepared from the corresponding tetra-
methyl ether (Dalton et al., 1980) by demethylation
with boron tribromide (Milgrom, 1983) rather than
hydrogen bromide or aniline hydrochloride
(Semeikin et al., 1983). It was also prepared by the
alkaline hydrolysis of meso-tetra(m-acetoxyphenyl)-
porphyrin in an analogous way to the para
compound (above). Mass spectrum (FAB): M+ +H,
679.
5, 10, 15, 20-Tetra(o-hydroxyphenyl)porphyrin
(IV) was prepared by ether cleavage (BBr3) of the
corresponding tetramethyl ether, and was obtained
as a mixture of atropisomers (Gottwald & Ullman,
1969) which was used as such in the biological
assay.
Porphyrins, I, III and IV were (apart from
atropisomers in the last case) single substances on
thin layer chromatography, and spectroscopic data
(electronic and nuclear magnetic resonance spectra)
confirmed the assigned structures.
HpD was prepared as previously described
(Bonnett et al., 1981). It was dissolved at a
concentration of 4mgml- in 0.5% sodium
bicarbonate (Analar British Drug Houses) in pH7.3
PBS. Photofrin II (2.5mgml-1) was a generous gift
of Photofrin Medical Inc.
Solutions All THPP's were soluble to some extent
in dimethyl sulphoxide (DMSO) and aqueous
alkali. However, o-THPP was so poorly soluble in
aqueous media that only a DMSO solution was
used (except for one experiment) and K-p-THPP
was poorly soluble in DMSO so only aqueous
solutions were used. p-THPP and K-p-THPP
dissolved well in 0.0125 M sodium hydroxide in
physiological saline, whereas m-THPP required
0.05 M sodium hydroxide for solution. For con-
venience, therefore, all aqueous solutions of THPP's
were in 0.05M sodium hydroxide in physiological
saline. Stocks of solutions were made such that
the required dose was given in 0.1ml 10g-1 body
weight of aqueous solution or 0.025ml lOg-1 of
DMSO. Solutions were stored at -20°C and
thawed just before use. The chemical stability of
these compounds in solution is under investiga-
tion. There was no detectable change in biological
activity over the period of storage, which was
generally a few weeks.
Drugs were administered on a mole/kg basis,
with molecular weights of 680 for p-, m- and o-
THPP, of 830 for K-p-THPP (Milgrom, 1983) and
an assumed molecular weight of 600 for HpD and
Photofrin II.
Absorbances 20yM solutions of THPP's were
prepared by injecting 40I1 of a 1.25mm solution in
DMSO into 2ml of foetal calf serum (Flow
Laboratories). Solutions of HpD and Photofrin II
were similarly prepared in foetal calf serum).
Absorbances were measured on a Beckman DU6
Spectrophotometer.
Light source An Oxford Lasers CulO copper-
vapour laser, pumping a DL 10K dye laser was
used. The dye was rhodamine 640. Light was
passed down a 1 mm fibre and had a divergence of
300 at the fibre end. By using a mechanical
attenuator in the beam or varying the distance
between fibre tip and target, light intensity
(measured with a 14BT thermopile (Laser
Instrumentation)) was kept in the range 200-
300mWcm-2, where thermal effects with red light
are negligible. Excitation wavelengths were 625nm
for Photofrin II and HpD, 656nm for p-THPP and
K-p-THPP and 648 nm for m- and o-THPP.NEW TUMOUR PHOTOSENSITISERS 719
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Animals
Inbred BALB/c mice of either sex were used,
weighing 16-22g at the start of an experiment. All
experiments on tumours (and tumour passage) were
carried out on female mice. Experiments on skin
were carried out in female mice (with one
exception) and experiments on brain in male mice,
but there were no evident sex-related differences in
effect.
Tumour necrosis
The method for measuring treatment-induced
tumour necrosis has been described in detail
(Berenbaum et al., 1982). Briefly, s.c. implants of
the PC6 plasma cell tumour were illuminated with a
light dose of OJCcm-2 at the appropriate wave-
length one day after injection of sensitiser.
The next day, 0.2ml of 1% Evans blue (Sigma)
in saline was given i.v., tumours removed into
formol saline 1 h later, and the depth of necrosis
measured on slices of the fixed tumour using a
dissecting microscope fitted with an eyepiece
graticule.
Skin damage
The skin of sensitised mice rapidly becomes
oedematous on exposure to light. This change was
assessed by weighing a disc of skin 1 cm in
diameter. Sensitised mice were shaved over the back
1-3 days before illumination and the area depilated
with Immac (Anne French, London) immediately
before illumination. Mice were anaesthetised with
'Equithesin' (Green, 1979) and a metal shield with
a cm diameter circular hole placed over the
upper lumbar region. (It was important to avoid
pressure on the skin by the shield as even this
moderate restriction of blood supply during
illumination substantially reduced damage). The
skin exposed by the hole was illuminated to a dose
of OJCcm-2 at the required wavelength. (Skin
showing active hair growth was not used). Four
hours later, mice were killed with ether. The dorsal
skin was removed, placed dermis down on the
absorbent side of a sheet of Benchkote
(Gallenkemp Ltd), the illuminated area of skin,
with supporting Benchkote, punched out with a
lcm diameter stainless steel punch and rapidly
weighed.
Control mice were either anaesthetised only or
exposed to light without having been sensitised. The
mean weight of the skin sample in these was
36+1 mg (n =22). Exposure of unsensitised mice to
OOJJcm-2 at any of the wavelengths used had no
effect on skin weight.
Brain damage
The procedure has been described in detail
previously (Berenbaum et al., 1986). Briefly, mice
were anaesthetised, the skin over the cranium was
reflected, the cranium exposed to a dose of
OJCcm-2 of light and the incision was then
sutured. Three hours later, 0.2ml of Evans blue in
10% bovine serum albumin was given i.v. and, 1 h
later, mice were killed with ether and brains crudely
homogenised in 20ml Harada's solution (Harada et
al., 1970). The next day the suspension was
centrifuged and the dye content of the supernate
measured by absorbance at 620nm. Mean Evans
blue brain content in control mice subjected to
anaesthesia and the surgical procedure only was
0.95+0.05ug (n= 13).
Damage index
To compare effects in the three tissues examined, a
Damage Index was calculated. For tumours, this
was simply the mean depth of tumour necrosis in
mm. For skin and brain the index was calculated
from mean skin sample weight or brain Evans blue
content as follows:
Damage Index=(Treated-Control)/Control
Thus, the index for undamaged tissues did not
differ significantly from zero, and an index of 1
implied an increase of 100% in skin sample weight
or brain Evans blue content.
Sensitisation
Solutions in 0.05M sodium hydroxide/saline were
given intravenously under brief ether anaesthesia in
a volume of 0.1 ml lOg- . Solutions in DMSO
were given i.p. generally in a volume of 0.025ml
0g-1. Injected mice were immediately placed in
subdued light and kept there until they were due to
receive laser treatement.
Results
The absorption spectra in foetal calf serum of the
agents used are shown in Figure 2. The wavebands
selected for use were 625nm for Photofrin II and
HpD, 656nm for p-THPP and its potassium salt
and 648 nm for m-THPP and o-THPP.
Tumours could be sensitised by HpD sufficiently
to show substantial necrosis (3-5mm) on exposure
to OJCcm-2 light but, at the large doses of
sensitiser needed for this effect (100-2001umkg-'),
skin photosensitisation was marked (Figure 3).
Even one week after injection of such doses ofNEW TUMOUR PHOTOSENSITISERS 721
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Figure 4 Dose-response curves for Photofrin II.
Details as in Figure 3.
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Figure 2 Absorption spectra of 25 /IM solutic
(----) Photofrin II, ( ) m-THPP, (-----) o-
and (-----) p-THPP in foetal calf serum contain
(v/v) DMSO. The spectra of HpD and K-p-THF
not shown as, over this range, they did not
materially from those of Photofrin II and p-
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Photofrin II was about 1.5 times as potent as
HpD in sensitising tumours, i.e., its dose-response
Do curve was shifted to the left by a distance
corresponding to a 1.5-fold reduction in dose
(Figure 4). The shift in the curves for skin and
ns of brain sensitisation was greater - Photofrin II was
THPP about twice as potent as HpD in inducing skin
ig 2% oedema at 3 days and in increasing cerebral vessel
diffre permeability to Evans blue. THPPe p-THPP and its potassium salt were 4-6 times as
potent (on a gMkg- 1 basis) as Photofrin II and 5-6
times as potent as HpD in sensitising tumours. p-
THPP was slightly more effective in sensitising
11 o tumours if given in DMSO i.p. rather than in
aqueous i.v. In contrast to HpD and Photofrin II,
p-THPP produced little sensitisation of skin at 3
days after injection except at high doses, and this
had vanished at 7 days. Substantial brain
sensitisation was not produced at any dose (Figure
5). The potassium salt of p-THPP behaved similarly
200
Figure 3 Dose-response curves for HpD after
exposure to OJCcm-2 light at 625nm (pooled results
of several experiments). Depth of tumour necrosis
(mm) (-). Damage index for brain (0). Damage index
for skin 3 days after sensitisation (-). Damage index
for skin 7 days after sensitisation (7). (For definition
of damage index, see text). Points show mean+s.e.
The number of samples per point for tumours is
indicated by each point. For skin and brain, there
were 5-7 samples per point.
HpD, exposure to this small dose of light caused an
acute increase of 100-200% in skin sample weight.
Cerebral photosensitisation was pronounced after
100pmkg-t of HpD, with intense blueing of the
brain surface.
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Figure 5 Dose-response curves for p-THPP after
exposure to 1OJcm-2 light at 656 nm. Depth of
tumour necrosis (in mm) after injection in aqueous
alkali i.v. (-). Depth of tumour necrosis after injection
in DMSO i.p. ([1). Other details as in Figure 3.
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(Figure 6), with the difference that virtually no skin
sensitisation was present even at 3 days after
injection.
o-THPP was about 12-16 times as potent as
HpD and tumour destruction to a mean depth of
7mm was achieved (Figure 7), but this was at the
cost of intense skin sensitisation. Even with doses
as low as 6.25gMkg-1 (which produced - 3.5mm
tumour necrosis), samples from skin illuminated 3
or 7 days later were four times the normal weight.
Evans blue injection showed that, at doses of
6.25gmkg 1 or above of o-THPP, skin exposed to
OJCcm-2 light 3 days later rapidly became
avascular (and the same happened on exposure at 7
days after 12.5-25 mkg-1). At these dose levels,
skin oedema was maximal and, at higher doses still
(50gmkg-1), it was reduced, presumably because
vascular damage was so marked as to compromise
blood flow to the illuminated area and its
surroundings.
The possibility that the intense cutaneous photo-
sensitisation induced by o-THPP was associated
3.125 6.25 12.5 25 50 100
Dose (jm kg-1)
Figure 6 Dose-response curves for K-p-THPP in
aqueous alkali i.v. after exposure to OJCcm-2 light at
656nm. Details as in Figure 3.
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with administration in DMSO was tested by
comparing the effects of low doses in both DMSO
and aqueous alkali (Figure 8). No differences were
apparent.
In brains illuminated after injecting o-THPP,
there was a slight increase in Evans blue levels over
a wide dose-range, but rarely discrete areas of
blueing of the cerebral surface.
m-THPP was the most potent tumour photo-
sensitiser in this series (Figure 9), being about 25-
30 times as potent as HpD. Solutions in aqueous
alkali and DMSO were equally effective. At doses
of 6.25jM kg-1, 4-5mm tumour necrosis was
x
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CE
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Figure 8 Dose-response curves for skin oedema after
sensitisation with o-THPP in aqueous alkali i.v. (7) or
in DMSO i.p. (V). Skin in male mice exposed to
1OJcm-2 light at 648nm 7 days after injection of
sensitiser. Groups of 5.
1.56 3.125 6.25 12.5 25 50
Dose (pum kg-')
100
Figure 7 Dose-response curves for o-THPP in DMSO
i.p. after exposure to OJCcm-2 light at 648nm. Details
as in Figure 3.
Dose (,um kg-')
Figure 9 Dose-response curves for m-THPP after
exposure to OJCcm-2 light at 648nm. Details as in
Figure 5.
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produced without detectable sensitisation of skin or
brain. Tumour necrosis to a mean depth of about
8 mm could be achieved but at the cost of
substantial cutaneous sensitisation. At a dosage of
15-35 JM kg-1, brain Evans blue levels were
moderately raised, but it was unusual to see discrete
areas of cerebral blueing. At a dose of 0S mkg-1,
10JCcm2 light to the cranium was lethal.
Preliminary investigations suggest damage to the
choroid plexus.
Discussion
Our initial aim, which was to find sensitisers
strongly activated at wavelengths above 625 nm and
obtainable in the pure state, has clearly been
achieved. Moreover, these sensitisers are effective in
vivo. Although they are considerably more potent
on a molar basis than HpD or Photofrin II,
differences in therapeutic potency are not in
themselves an over-riding consideration as they
could, other things being equal, be overcome
merely by adjusting dosage. The limits on such
adjustments are set mainly by toxicities for normal
tissues, and thus the main consideration must be
relative selectivity for tumours and normal tissues.
When comparing toxic drugs, a useful
operational approach is to decide a maximum
acceptable level of toxicity and to determine the
therapeutic effects achievable within these toxic
limits. These limits may be decided by reference to
the supposed situation in man. There is necessarily
an element of arbitrariness in any such judgement
but, for the purposes of comparison, we set as toxic
limits an increase of 100% in skin sample thickness
at 3 days after sensitisation, an increase of 50% at
7 days (to take into account persistence of
sensitisation) and an increase of 100% in brain
Evans blue levels. The results of our comparison
are shown in Table I, from which the following
conclusions may be drawn.
In these experiments, we could not produce useful
levels of tumour necrosis (>2mm) with Photofrin II
without sensitising skin to an unacceptable degree.
HpD was a little more selective (2.5 mm necrosis
within the acceptable limit). p-THPP and its
potassium salt had considerable therapeutic advan-
tages over the first two agents (4-5mm necrosis
within acceptable limits of skin toxicity) and m-
THPP was even better (5-6mm necrosis). o-THPP
gave unacceptable skin sensitisation at doses
(3.125pumkg-1) that were quite ineffective in
sensitising tumours.
So far as brain sensitisation was concerned, HpD
and Photofrin II did not produce useful levels of
tumour necrosis except at doses producing
unacceptable toxicity. Brain photosensitisation was
within acceptable limits at all doses of p-THPP, its
potassium salt or o-THPP, and tumour necrosis of
at least 5-7mm depth could be achieved within
these limits. Although m-THPP did not cause an
unacceptable increase in brain permeability to
Evans blue at any dose, at the highest dose level
(50 JM kg-1), it caused a lethal cerebral photo-
sensitisation, possibly by an action on the choroid
plexus. At doses low enough to avoid this effect, 7-
9 mm tumour necrosis was produced.
The arbitrary nature of the limits set must be
stressed, but examination of the dose-response
curves in Figures 3-9 suggests that setting different
levels for these limits would not materially alter the
conclusions that may be drawn as to the relative
selectivities of the agents studied. However, there is
room for argument as to whether effects exceeding
these toxic limits would indeed by unacceptable in
a clinical setting. The consequences of skin
sensitisation may be avoided by keeping the patient
in subdued light, which would be a small price if
the cure of malignant tumours could thereby be
assured, but the likelihood of achieving this may be
much greater with potent tumour sensitisers such as
those described here than with the much less
effective HpD and Photofrin II.
The marked cerebral photosensitivity produced
by Photofrin II and HpD is not a consideration in
extra-cranial phototherapy, so the unacceptability
or otherwise of the limit we set is relevant only in
treating brain tumours. Here, the lack of
sensitisation by p-THPP and its potassium salt at
doses that cause substantial tumour sensitisation
appears promising. The low increase in brain
Table I Depths of tumour necrosis achieved within limiting toxicity levels.
Mean depth (mm) oftumour necrosis at limit oftoxicity
Limiting toxicity
Tissue index Photofrin II HpD p-THPP K-p-THPP o-THPP m-THPP
Skin, day 3 1.0 2 2.5 4-4.5 >4.5 0 5-5.5
Skin, day7 0.5 <2 2 >5 >4.5 0 6
Brain, day I 1.0 <1.5 2 >5 >4.5 >7 7-9724 M.C. BERENBAUM et al..
permeability induced by o-THPP over a wide dose
range and the cerebral photosensitivity produced at
high doses of m-THPP indicate the need for further
investigation and caution with these drugs.
The results of our comparison of HpD and
Photofrin II were somewhat unexpected. In
preliminary clinical studies, Dougherty (1984)
found that 1.5-2.0mgkg-1 Photofrin II had about
the same tumour sensitising effect as 3mgkg-1
HpD, a potency differences of 1.5-2-fold, which
agrees well with our results in mice. However, there
was no difference in ability to sensitise skin
(patients could be given smaller doses of Photofrin
II than of HpD, so skin effects were thereby
reduced). In contrast, we found that Photofrin II
was about twice as potent as HpD in inducing skin
(and brain) photosensitisation, so that the overall
advantage would be on the side of HpD. We have
no ready explanation for our discordant findings.
However, HpD varies from batch to batch and it is
possible that we were accidentally fortunate in the
batch we prepared for these experiments.
Alternatively, we may be dealing with a species-
related difference.
It is worth considering possible explanations for
the increased effectiveness and improved selectivity
of the new compounds used here. Their red
absorption bands are all at longer wavelengths than
those of HpD and Photofrin II, but the differences
are not large (656 and 648 nm compared with
625nm) and would not produce a large increase in
tissue penetration by light (Eichler et al., 1977; Wan
et al., 1981). In any case, the sensitisers activated at
648 nm (o-THPP and m-THPP) are considerably
more potent than those activated at the longer
wavelength 656nm (p-THPP and its potassium salt)
and molar absorption by m-THPP at 648nm is
only half that of p-THPP at 656nm (Figure 2),
showing that penetration of tissues and absorption
of light are not the main determinants of activity.
The comparative abilities of these agents to
generate singlet oxygen in vivo may be important,
but we have as yet no evidence on this point.
The strongest evidence that these photophysical
factors are not predominating is that relative
selectivity for different tissues varies between these
compounds. For instance, both m-THPP and o-
THPP are activated at 648nm and absorb equally
at that wavelength (so differences in tissue
penetration by light and light absorption by the
sensitiser cannot explain the biological differences
between them) yet the former is twice as potent as
the latter in sensitising tumours and only about a
quarter as potent in sensitising skin. Such
phenomena suggest that the major determinants of
effectiveness and selectivity are ability to localise in
crucial tissue sites, and this will vary from one
tissue to another with the physicochemical
properties of the agent. It may be relevant that, in
this small series of tetra(hydroxyphenyl)porphyrins,
ability to sensitise skin is inversely correlated with
ease of aqueous solution. In the brain, we suppose
that these compounds, like HpD and Photofrin II,
are excluded by the normal blood-brain barrier but
that, unlike these agents, they do not undergo the
persistent binding to cerebral small vessels that we
think explains their brain-photosensitising effect
(Berenbaum et al., 1986). Again, this difference
probably has a physicochemical basis.
The compounds described here thus appear to be
promising. Their therapeutic use in tumours of
particular sites will depend, inter alia, on selectivity
for important local normal tissues, and each site
requires investigation as an individual case in this
regard.
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